hepatitis

[Nature Communications] Scientists identified and characterized a remarkable mutational mechanism in human hepatocellular carcinoma caused by Hepatitis B virus, by which DNA molecules from the virus were inserted into the tumor genome causing dramatic changes in its configuration, including non-homologous chromosomal fusions, dicentric chromosomes and megabase-size telomeric deletions.

[Revive Therapeutics Ltd.] Revive Therapeutics Ltd. announced that it has filed an application with the US FDA to receive Orphan Drug Designation for Bucillamine for the prevention of ischemia–reperfusion injury during liver transplantation.

[Singapore Health Sciences Authority] Singapore-based SCG Cell Therapy Pte Ltd has signed an agreement with the Cell Therapy Facility of Singapore Health Sciences Authority for the evaluation and validation of SCG’s proprietary cell therapy manufacturing process to develop a new treatment option for patients with Hepatitis B virus related hepatocellular carcinoma.

[Hepatic Cell News] Elevar Therapeutics, Inc. announced that the US FDA has granted rivoceranib with orphan drug designation for the treatment of HCC, the most common primary liver malignancy and is a leading cause of cancer-related death worldwide.

[Angewandte Chemie-International Edition] By embedding the hepatitis C virus NS3 protease between the single-chain variable fragment and the hinge domain, investigators showed that the display of anti-CD19 single-chain variable fragment on CAR-T cells was positively correlated to the presence of a clinical hepatitis C virus NS3 protease inhibitor asunaprevir.

[Scientific Reports] The authors sampled 175 hepatocellular carcinoma, 117 cirrhotic and 165 non-cirrhotic controls from a prospective cohort study of chronically hepatitis B virus-infected individuals to assess immunologic markers in relation to liver disease.